The good, the bad, and the ugly: Providing highly active antiretroviral therapy when it is most difficult

Clinical Infectious Diseases

Volumn 42, Issue 11, 2006, Pages 1636-1638

  Flanigan, Timothy P ^a   Mitty, Jennifer A ^a  

^a MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE; METHADONE;

ADULT; CASE REPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INTRAVENOUS DRUG ABUSE; MALE; MEDICAL DECISION MAKING; NOTE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIRECTLY OBSERVED THERAPY; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33646729695     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503916     Document Type: Note

References (13)

1. Riley ED, Bangsberg DR, Guzman D, Perry S, Moss AR. Antiretroviral therapy, hepatitis C virus and AIDS mortality among San Francisco's homeless and marginally housed. J Acquir Immune Defic Syndr 2005; 38:191-5.
2. Lucas GM, Mullen A, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42:1628-35 (in this issue).
3. Wohl AR, Garland WH, Valencia R. A randomized trial of directly administered antiretroviral therapy and adherence care management intervention. Clin Infect Dis 2006; 42:1619-27 (in this issue).
4. Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med 2001; 110:664-6.
5. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002; 12:305-6.
6. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replications. Clin Infect Dis 2004; 38(Suppl 5):S376-87.
7. Mitty JA, Macalino GE, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005; 39:545-50.
8. Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001; 358:404-9.
9. Wohl AR, Garland WH, Squires K, et al. The feasibility of a community-based directly administered antiretroviral therapy program. Clin Infect Dis 2004; 38(Suppl 5):S388-92.
10. Mitty JA, Hogan JW, Macalino GE, et al. A randomized controlled trial of modified directly observed HAART (MDOT) vs. standard of care (SOC) among HIV+ active substance users [abstract 783]. In: Program and abstracts of the 42 Annual Meeting of the Infectious Disease Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2005:172.
11. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27:251-9.
12. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002; 17:377-81.
13. Moore RD, Keruly JC, Chaison RE. Differences in HIV disease progression by injecting drug use in HIV-injected person in care. J Acquir Immune Defic Syndr 2004; 35:46-51.